{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:22:38Z","timestamp":1769242958080,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.hoc.2023.07.002","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:14:12Z","timestamp":1693451652000},"page":"1077-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Parth S.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.07.002_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hoc.2023.07.002_bib2","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther Adv Hematology"},{"key":"10.1016\/j.hoc.2023.07.002_bib3","doi-asserted-by":"crossref","first-page":"780085","DOI":"10.3389\/fonc.2021.780085","article-title":"Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features","volume":"11","author":"van der Straten","year":"2021","journal-title":"Frontiers Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib4","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management","volume":"38","author":"Jain","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjh.17383","article-title":"Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation","volume":"194","author":"Kumar","year":"2021","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hoc.2023.07.002_bib6","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib8","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.07.002_bib10","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1097\/HS9.0000000000000745","article-title":"A\u00a0Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.hoc.2023.07.002_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib12","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.07.002_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12885-023-10546-6","article-title":"Clinical outcomes in patients relapsed\/refractory after \u22652 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis","volume":"23","author":"Kanters","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2023.07.002_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.07.002_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/jpm12030376","article-title":"Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors","volume":"12","author":"Burkart","year":"2022","journal-title":"J\u00a0Personalized Medicine"},{"key":"10.1016\/j.hoc.2023.07.002_bib17","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hoc.2023.07.002_bib18","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib20","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib21","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.07.002_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib24","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Stephen","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"at the U. of. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2023.07.002_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib30","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Medicine"},{"key":"10.1016\/j.hoc.2023.07.002_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib32","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.07.002_bib33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib35","first-page":"JCO2201797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib37","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T\u00a0cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2023.07.002_bib39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib40","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib42","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2015-11-624320","article-title":"The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma","volume":"127","author":"Kuruvilla","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib43","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1634\/theoncologist.2019-0138","article-title":"Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs","volume":"24","author":"Matasar","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib44","first-page":"1","article-title":"Long-term outcomes following CAR T\u00a0cell therapy: what we know so far","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib45","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40487-021-00161-5","article-title":"Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies","volume":"9","author":"Rodgers","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.hoc.2023.07.002_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CMAR.S381493","article-title":"Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab","volume":"15","author":"Lopedote","year":"2023","journal-title":"Cancer Management Res"},{"key":"10.1016\/j.hoc.2023.07.002_bib49","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1182\/blood-2022-159544","article-title":"Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.002_bib50","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.07.002_bib51","doi-asserted-by":"crossref","first-page":"1227308","DOI":"10.1155\/2022\/1227308","article-title":"Parallel CD19\/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In\u00a0Vitro and In\u00a0Vivo","volume":"2022","author":"Yin","year":"2022","journal-title":"Evid-based Compl Alt"},{"key":"10.1016\/j.hoc.2023.07.002_bib52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.07.002_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.07.002_bib54","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","article-title":"ROR1-targeting switchable CAR-T cells for cancer therapy","volume":"41","author":"Peng","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2023.07.002_bib55","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:21:25Z","timestamp":1760185285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0889858823001041"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.07.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}